Microbicides for HIV prevention: reality or hope?
Author:
- 1 February 2010
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Infectious Diseases
- Vol. 23 (1) , 26-31
Abstract
This review discusses recent developments within the field of microbicide development and considers whether there are grounds to be hopeful that it will be possible to develop a microbicide for the prevention of HIV infection. Phase 2B/3 effectiveness studies of surfactant and polyanion vaginal microbicides have demonstrated modest or no effect against HIV infection and in the case of nonoxynol-9 and cellulose sulfate the potential to increase the risk of HIV acquisition. However, newer antiretroviral microbicide candidates, such as tenofovir, have shown good safety and significant efficacy in animal models and human tissue explant systems and are currently being evaluated in human effectiveness studies. New formulation platforms, such as vaginal rings, are being developed to optimize product acceptability and adherence, and far greater scrutiny of candidate microbicides is happening at both the preclinical and early clinical phase of development. Drug development is an inherently high-risk activity and many promising candidates are discarded due to safety issues or lack of efficacy. Lessons learned over the last two decades have helped to improve the microbicide development pathway and provide hope that it will be possible to develop a safe and effective microbicide for HIV prevention.Keywords
This publication has 50 references indexed in Scilit:
- Design, expression, and characterization of a multivalent, combination HIV microbicideThe FASEB Journal, 2009
- Topically Applied Recombinant Chemokine Analogues Fully Protect Macaques from Vaginal Simian‐Human Immunodeficiency Virus ChallengeThe Journal of Infectious Diseases, 2009
- Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide componentProceedings of the National Academy of Sciences, 2009
- Chemokine Analogues Show Suitable Stability for Development as MicrobicidesJAIDS Journal of Acquired Immune Deficiency Syndromes, 2008
- Bioengineering Lactic Acid Bacteria to Secrete the HIV-1 Virucide CyanovirinJAIDS Journal of Acquired Immune Deficiency Syndromes, 2005
- Transgenic plant production of Cyanovirin‐N, an HIV microbicideThe FASEB Journal, 2005
- Cyanovirin-N Inhibits AIDS Virus Infections in Vaginal Transmission ModelsAIDS Research and Human Retroviruses, 2004
- Cyanovirin-N Gel as a Topical Microbicide Prevents Rectal Transmission of SHIV89.6P in MacaquesAIDS Research and Human Retroviruses, 2003
- Cyanovirin-N, a Potent Human Immunodeficiency Virus-Inactivating Protein, Blocks both CD4-Dependent and CD4-Independent Binding of Soluble gp120 (sgp120) to Target Cells, Inhibits sCD4-Induced Binding of sgp120 to Cell-Associated CXCR4, and Dissociates Bound sgp120 from Target CellsAntimicrobial Agents and Chemotherapy, 2001
- Variable Sensitivity of CCR5-Tropic Human Immunodeficiency Virus Type 1 Isolates to Inhibition by RANTES AnalogsJournal of Virology, 2000